1-2 of 2 results for subject:Pfizer
Librarians' tools
- Search time
- 0.163 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
More
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask Her Majesty’s Government what consideration they have given to using the purchasing power of the National Health Service as a major customer of AstraZeneca and Pfizer to ensure that Pfizer honours any undertakings given in the event of a successful takeover of AstraZeneca.[HL6985]
To ask Her Majesty’s Government what consideration they have given to using the purchasing power of the National Health Service as a major customer of AstraZeneca and Pfizer to ensure that Pfizer honours any undertakings given in the event of a successful takeover of AstraZeneca.[HL6985]
Both companies supply the National Health Service with vital medicines that are used to treat millions of patients each year. It is for clinicians to make prescribing decisions based on their
patient’s individual clinical circumstances and our priority is to ensure that patients continue to get the medicines they need.
To ask Her Majesty’s Government, for each of the last three years for which figures are available, what was the total National Health Service expenditure on drugs and medicines produced by (1) AstraZeneca, (2) Pfizer, and (3) GlaxoSmithKline; and what percentage of the National Health Service’s total expenditure on drugs...
To ask Her Majesty’s Government, for each of the last three years for which figures are available, what was the total National Health Service expenditure on drugs and medicines produced by (1) AstraZeneca, (2) Pfizer, and (3) GlaxoSmithKline; and what percentage of the National Health Service’s total expenditure on drugs...
The following table sets out for 2011, 2012 and 2013, National Health Service spend on medicines and percentage of spend, for AstraZeneca, Pfizer and GlaxoSmithKline in primary care only.
This does not include data on NHS use of medicines in hospitals, as comparable current data sources do not take account of the discounts available.
| Net
ingredient cost and proportion of all primary care spend by
manufacturer, in England, for the years 2011, 2012 and 2013, based on
prescription items dispensed in the community in
England.1 | ||||||
| 2011 | 2012 | 2013 | ||||
| Manufacturer
name | Net
Ingredient Cost
(£000s) | Percentage
of all Primary
Care | Net
Ingredient Cost
(£000s) | Percentage
of all Primary
Care | Net
Ingredient Cost
(£000s) | Percentage
of all Primary
Care |
| AstraZeneca | 451,931 | 5.5 | 366,037 | 4.7 | 353,981 | 4.5 |
| Pfizer | 771,631 | 9.5 | 521,610 | 6.7 | 408,643 | 5.2 |
| GlaxoSmithKline | 597,634 | 7.3 | 565,881 | 7.2 | 542,992 | 6.9 |
| Total
(all primary care expenditure on medicines in
England2) | 8,164,364 | 100.0 | 7,840,390 | 100.0 | 7,888,304 | 100.0 |
Source:
Prescription Cost Analysis provided by the Health and Social Care Information Centre
Notes:1.
This may not include spend on those medicines made by the companies that are also available generically.2.
This total relates to all medicines contained within British National Formulary (BNF) Chapters 1 to 19. The cost of dressings and appliances contained within BNF Chapters 20 to 23 has been excluded.